Antibody drugs, due to their high specificity and significant therapeutic effects, possess superior pharmacokinetic properties, making them a crucial player in the biopharmaceutical market. According to Frost & Sullivan’s statistical predictions, the global antibody drug market is expected to reach $443.1 billion by 2030. As the demand for antibody drugs continues to grow, the development […]
On November 30, 2023, Inipharm, a pharmaceutical company focused on severe liver diseases, announced the initiation of a Phase I clinical study for its oral drug INI-822. INI-822 is the first small molecule inhibitor of HSD17B13 to enter clinical development, and it is also the first clinical candidate developed by Inipharm, primarily intended for the […]
Antibody-Drug Conjugates (ADCs) are a novel class of cancer drugs that combine three main components: a monoclonal antibody, a linker, and a toxin. By harnessing the specificity of antibodies and the potency of cytotoxic agents, ADCs can selectively target and kill tumor cells, while sparing healthy cells. The choice of toxin is critical for the […]
On December 7, 2023, AbelZeta announced a collaboration with AstraZeneca to jointly develop C-CAR031, a chimeric antigen receptor T-cell (CAR-T) therapy targeting Glypican-3 (GPC3) for hepatocellular carcinoma (HCC). According to the agreement, AbelZeta is eligible for milestone payments and licensing fees for its global development. The drug will be exclusively developed, manufactured, and commercialized by […]
As of December 31, 2023, the FDA records that a total of 55 new drugs were approved in 2023. Among them, 12 are antibody drugs, including 8 single antibodies and 4 bispecific antibodies. Come and check if your points of interest are among them.
GPRC5D, identified as a G protein-coupled orphan receptor, demonstrates limited expression in normal tissues.
Identifying targets that are expressed on tumor cells but not or lowly expressed in normal cells is crucial for tumor immunity. ROR1 is a highly promising drug target, exhibiting differentiated high expression in various solid tumors and hematologic malignancies, while not expressing in adult healthy tissues. This suggests that ROR1 holds the potential to become […]
At the end of 2020, Genmab and ADC Therapeutics announced the termination of clinical development for Enapotamab vedotin and ADCT-601, respectively, due to their failure to meet expected outcomes in early trials. Both drugs were antibody-drug conjugates (ADCs) targeting AXL. Enapotamab vedotin was coupled with the microtubule inhibitor MMAE, while ADCT-601 was coupled with the […]
The 5T4 protein, also known as Wnt-activated inhibitory factor 1 (WAIF1) or Trophoblast Glycoprotein (TPBG), is a glycoprotein found in embryonic trophoblast cells. It has been identified as a treatment target for solid tumors due to its abundance in cancerous tissues and limited expression in normal tissues. Currently, there are approximately nine investigational drugs targeting […]
Antibody-drug conjugates (ADCs) mainly consist of monoclonal antibodies, linkers, and cytotoxic payloads. The antibody, acting as the “missile” in ADC drugs, possesses target-specific functionality. It can selectively recognize tumor cell surface antigens, undergo internalization upon binding to these antigens, and deliver the cytotoxic payload to tumor cells to exert its toxic effects. Since not all […]